We are live on ! Find out more
ALDR

Alder Biopharmaceuticals
ALDR

Delisted

ALDR was delisted on the 21st of October, 2019.

Back to rankings

145 hedge funds and large institutions have $1.11B invested in Alder Biopharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 65 increasing their positions, 38 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

333% more call options, than puts

Call options by funds: $2.78M | Put options by funds: $642K

71% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 38

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

9% less funds holding

Funds holding: 159 → 145 (-14)

36% less capital invested

Capital invested by funds: $1.73B → $1.11B (-$620M)

43% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 30

Holders
145
Holders Change
-14
Holders Change %
-8.81%
% of All Funds
3.63%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
17
Increased
65
Reduced
38
Closed
30
Calls
$2.78M
Puts
$642K
Net Calls
+$2.14M
Net Calls Change
+$10.3M

Top Buyers

1
PHS
PFM Health Sciences
California
+$23.6M
2
JHIU
Janus Henderson Investors US
Colorado
+$9.57M
3
CCP
Clough Capital Partners
Massachusetts
+$7.65M
4
BFA
BlackRock Fund Advisors
California
+$7.24M
5
State Street
State Street
Massachusetts
+$6.97M

Top Sellers

1
SIG
Senator Investment Group
New York
-$32.8M
2
Citadel Advisors
Citadel Advisors
Florida
-$20.8M
3
Marshall Wace
Marshall Wace
United Kingdom
-$12.2M
4
Asset Management One
Asset Management One
Japan
-$9.69M
5
DCM
Driehaus Capital Management
Illinois
-$7.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
DILH
151
Dai-ichi Life Holdings
Japan
– -$1.23M -37,623 Closed
EIM
152
Essex Investment Management
Massachusetts
– -$1.06M -32,406 Closed
AQR Capital Management
153
AQR Capital Management
Connecticut
– -$764K -23,319 Closed
ECM
154
Endurant Capital Management
California
– -$639K -19,500 Closed
GAMA
155
Graticule Asia Macro Advisors
New York
– -$639K -19,500 Closed
D.E. Shaw & Co
156
D.E. Shaw & Co
New York
– -$593K -18,109 Closed
PCM
157
Prelude Capital Management
New York
– -$530K -16,162 Closed
GTC
158
Ghost Tree Capital
New York
– -$524K -16,000 Closed
AP
159
AHL Partners
United Kingdom
– -$512K -15,649 Closed
Neuberger Berman Group
160
Neuberger Berman Group
New York
– -$475K -14,500 Closed
TAM
161
Tocqueville Asset Management
New York
– -$382K -11,650 Closed
Jane Street
162
Jane Street
New York
– -$332K -10,124 Closed
M&T Bank
163
M&T Bank
New York
– -$323K -9,849 Closed
SSA
164
Schonfeld Strategic Advisors
New York
– -$305K -9,321 Closed
GLRA
165
Gerald L. Ray & Associates
Texas
– -$298K -9,100 Closed
VEA
166
Virtus ETF Advisers
New York
– -$281K -8,582 Closed
Principal Financial Group
167
Principal Financial Group
Iowa
– -$273K -8,336 Closed
Stifel Financial
168
Stifel Financial
Missouri
– -$234K -7,122 Closed
CCMH
169
Cornerstone Capital Management Holdings
New York
– -$185K -5,662 Closed
Group One Trading
170
Group One Trading
Illinois
– -$22.2K -853 Closed
GAM
171
Gemmer Asset Management
California
– -$4K -125 Closed
GT
172
Glenmede Trust
Pennsylvania
– -$1K -31 Closed
Northwestern Mutual Wealth Management
173
Northwestern Mutual Wealth Management
Wisconsin
– +$520 +20 New
Simplex Trading
174
Simplex Trading
Illinois
– +$754 +29 New
3 4 5 6
7

ALDR Hedge Fund Activity: Q4 2016 in Review

145 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q4 2016, worth a combined $1.11B — down 36% from $1.73B a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of ALDR and 17 opened new positions — a net loss of 13 holders — while 38 trimmed existing stakes and 65 added.

The largest buyer was PFM Health Sciences, adding an estimated $23.6M. The largest seller was Senator Investment Group, exiting entirely with an estimated $32.8M sold.

  • 145 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q4 2016, down from 159 in Q3 2016.
  • Funds reported $1.11B of Alder Biopharmaceuticals stock for Q4 2016, down 36% quarter-over-quarter.
  • 17 funds opened new Alder Biopharmaceuticals positions in Q4 2016 and 30 closed out, a net change of -13 holders.
  • The largest Alder Biopharmaceuticals buyer in Q4 2016 was PFM Health Sciences, an estimated $23.6M added.
  • The largest Alder Biopharmaceuticals seller in Q4 2016 was Senator Investment Group, an estimated $32.8M sold.

Based on aggregated 13F filings for Q4 2016.